We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proximagen Grp | LSE:PRX | London | Ordinary Share | GB00B06FMX57 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 365.25 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMPRX
RNS Number : 2657I
Proximagen Group PLC
23 July 2012
TR-1:NOTIFICATION OF MAJOR INTEREST IN SHARES ------------------------------------------------------------------------------------ 1. Identity of the issuer or the underlying Proximagen Group plc issuer of existing shares to which voting rights are attached: (ii) --------------------------------------------------- ------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ------------------------------------------------------------------------------------ An acquisition or disposal of voting rights X ------------------------------------------------------------------------------ ---- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------------------ ---- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------------------ ---- An event changing the breakdown of voting rights ------------------------------------------------------------------------------ ---- Other (please specify): -------------------- -------------------------------------------------------- ---- 3. Full name of person(s) subject Upsher-Smith Laboratories, Inc. to the notification obligation: (iii) --------------------------------------------- ------------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) --------------------------------------------- ------------------------------------- 5. Date of the transaction and date 20 July 2012 on which the threshold is crossed or reached: (v) --------------------------------------------- ------------------------------------- 6. Date on which issuer notified: 20 July 2012 --------------------------------------------- ------------------------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 15% --------------------------------------------- ------------------------------------- 8. Notified details: -------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) -------------------------------------------------------------------------------------------------------------------------- Class/type of Situation previous Resulting situation after the triggering shares to the triggering transaction transaction if possible using the ISIN CODE --------------- ------------------------------------------ ------------------------------------------------------------- Number Number Number Number of voting % of voting of of of shares rights rights (x) Shares Voting Rights ------------- -------------------- -------------------- ------------- ---------------------- ---------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ---- ----- ------- --- ------ ------- ------------- ------- ------------- --------- ----------- GB00B06FMX57 10,015,700 10,015,700 0 0 10,015,700 0% 15.87% -------------------- -------------------- ------------- ------- ------------- --------- ----------- B: Qualifying Financial Instruments -------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------- Type of financial Expiration Exercise/ Number of voting % of voting instrument date (xiii) Conversion Period rights that may rights (xiv) be acquired if the instrument is exercised/ converted. --------------------- ------------------- ------------------------------ --------------------------- ----------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) -------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date (xvii) Conversion rights instrument rights (xix, instrument period refers to xx) (xviii) ------------- ------------- -------------------- --------------- ------------------------ --------------------------- Nominal Delta ------------- ------------- -------------------- --------------- ------------------------ ---------------- --------- Total (A+B+C) -------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------------------------- ----------------------------------------------------- 10,015,700 15.87% ------------------------------------------------------------------- ----------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ---------------------------------------------------------------------------------- USL Pharma International UK Limited is a direct, wholly-owned subsidiary of Upsher-Smith Laboratories, Inc. Pursuant to the transaction notified in this form, USL Pharma International UK Limited has acquired 10,015,700 shares in Proximagen Group plc (with all voting rights attached thereto) from Upsher-Smith Laboratories, Inc. Proxy Voting: ---------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------ -------------------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------ -------------------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------ -------------------------- 13. Additional information: ------------------------------------------ -------------------------------------- 14. Contact name: Stephen M. Robinson ------------------------------------------ -------------------------------------- 15. Contact telephone number: +1 763 315 2000 ------------------------------------------ --------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUOUARUWABUAR
1 Year Proximagen Neuroscience Chart |
1 Month Proximagen Neuroscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions